Cui Shanpeng, Han Qiuyuan, Zhang Ran, Zeng Siyao, Shao Ying, Li Yue, Li Ming, Liu Wenhua, Zheng Junbo, Wang Hongliang
Department of Critical Care Medicine, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang Province, China.
Future Medical Laboratory, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, Heilongjiang Province, China.
BMC Infect Dis. 2025 Jan 2;25(1):10. doi: 10.1186/s12879-024-10402-3.
The rapid evolution of the COVID-19 pandemic and subsequent global immunization efforts have rendered early metabolomics studies potentially outdated, as they primarily involved non-exposed, non-vaccinated populations. This paper presents a predictive model developed from up-to-date metabolomics data integrated with clinical data to estimate early mortality risk in critically ill COVID-19 patients. Our study addresses the critical gap in current research by utilizing current patient samples, providing fresh insights into the pathophysiology of the disease in a partially immunized global population.
One hundred elderly patients with severe COVID-19 infection, including 46 survivors and 54 non-survivors, were recruited in January-February 2023 at the Second Hospital affiliated with Harbin Medical University. A predictive model within 24 h of admission was developed using blood metabolomics and clinical data. Differential metabolite analysis and other techniques were used to identify relevant characteristics. Model performance was assessed by comparing the area under the receiver operating characteristic curve (AUROC). The final prediction model was externally validated in a cohort of 50 COVID-19 elderly critically ill patients at the First Hospital affiliated with Harbin Medical University during the same period.
Significant disparities in blood metabolomics and laboratory parameters were noted between individuals who survived and those who did not. One metabolite indicator, Itaconic acid, and four laboratory tests (LYM, IL-6, PCT, and CRP), were identified as the five variables in all four models. The external validation set demonstrated that the KNN model exhibited the highest AUC of 0.952 among the four models. When considering a 50% risk of mortality threshold, the validation set displayed a sensitivity of 0.963 and a specificity of 0.957.
The prognostic outcome of COVID-19 elderly patients is significantly influenced by the levels of Itaconic acid, LYM, IL-6, PCT, and CRP upon admission. These five indicators can be utilized to assess the mortality risk in affected individuals.
新冠疫情的迅速演变以及随后的全球免疫接种努力使得早期代谢组学研究可能过时,因为这些研究主要涉及未接触过病毒、未接种疫苗的人群。本文提出了一种基于最新代谢组学数据并结合临床数据开发的预测模型,用于估计重症新冠患者的早期死亡风险。我们的研究通过使用当前患者样本解决了当前研究中的关键差距,为部分免疫的全球人群中该疾病的病理生理学提供了新的见解。
2023年1月至2月,在哈尔滨医科大学附属第二医院招募了100例重症新冠感染老年患者,其中46例存活,54例死亡。利用血液代谢组学和临床数据建立入院24小时内的预测模型。采用差异代谢物分析等技术识别相关特征。通过比较受试者操作特征曲线下面积(AUROC)评估模型性能。最终预测模型在同期哈尔滨医科大学附属第一医院的50例新冠重症老年患者队列中进行外部验证。
存活者与非存活者之间在血液代谢组学和实验室参数方面存在显著差异。一种代谢物指标——衣康酸,以及四项实验室检查(淋巴细胞计数、白细胞介素-6、降钙素原和C反应蛋白)被确定为所有四个模型中的五个变量。外部验证集表明,在四个模型中,KNN模型的AUC最高,为0.952。当考虑50%的死亡风险阈值时,验证集的敏感性为0.963,特异性为0.957。
入院时衣康酸、淋巴细胞计数、白细胞介素-6、降钙素原和C反应蛋白的水平对新冠老年患者的预后结果有显著影响。这五个指标可用于评估受影响个体的死亡风险。